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A B S T R A C T
Objectives: This study aims to monitor the prevalence of suppurative otitis media in remote Indigenous
communities after introduction of 13-valent pneumococcal conjugate vaccine (PCV13) in October 2011.
We previously reported a decline in suppurative OM following replacement of PCV7 by 10-valent pneu-
mococcal Haemophilus inﬂuenzae protein D conjugate vaccine (PHiD-CV10) in October 2009.
Methods: We continued regular surveillance in remote Indigenous communities between February 2010
and August 2013. This analysis reports the general health, otitis media (OM), nasopharyngeal (NP) car-
riage and middle ear microbiology in children less than 36 months of age who received a primary course
of at least two doses of PHiD-CV10 or PCV13, and notmore than one dose of another pneumococcal vaccine.
Results: Mean ages of 511 PHiD-CV10- and 140 PCV13-vaccinated children were 19 and 13 months, re-
spectively. Most children received 3-dose non-mixed PCV schedules. At the time of assessment, general
health was poor and prevalence of risk factors was high in both groups: overall, around 14% of children
had scabies, 20% had impetigo, 59% had runny nose and 39% had cough. Average household size was 8
persons, and 60% of the mothers smoked. Bilaterally normal middle ears were detected in 10% and 7%,
respectively. OM with effusion (OME), almost all bilateral, was diagnosed in 52% and 50%, any suppura-
tive OM (acute OM or any tympanic membrane perforation [TMP]) in 37% and 41%, and TMP in 14% and
12%, respectively. Children in the PCV13 group had signiﬁcantly less NP carriage of combined Strepto-
coccus pneumoniae (Spn) and non-typeableHaemophilus inﬂuenzae (NTHi) (62% versus 51%) but signiﬁcantly
more polymicrobial (Spn and NTHi) middle ear cultures (12% versus 43%), and signiﬁcantly less Staph-
ylococcus aureus-positive middle ears (40% versus 7%). Although NP carriage of pneumococcal serotype
19A was low in the PCV13 group, serotypes 19F and 23F persist.
Conclusions: The general health, particularly ear health, of little children in remote Australian Indige-
nous communities remains in crisis. In particular, transition to PCV13 did not show substantial further
improvement in ear health. Possible vaccine-related differences in microbiology, including potential ben-
eﬁcial effects of PHiD-CV10 on NTHi infection, need to be further evaluated in randomised trials.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
Community based surveillance before [1] and after [2] the in-
troduction of each pneumococcal conjugate vaccine (PCV) has
highlighted the poor general health, and particularly high preva-
lence of otitis media, of Australian Indigenous children living in
remote Northern Territory (NT) communities. Throughout this period,
among children at a mean age of around 20 months, less than 10%
had bilateral aerated (normal) middle ears, ~30% had skin sores or
scabies, ~60% had a wet or dry cough, ~50% had a runny nose, and
~30% had abnormal haemoglobin [2]. Although the prevalence of
Abbreviations: AOMwiP, acute otitis media with perforation; AOMwoP, acute otitis
media without perforation; CI, conﬁdence interval; CSOM, chronic suppurative otitis
media; DP, dry perforation; IPD, invasive pneumococcal disease; Mcat, Moraxella
catarrhalis; mo, month; NT, Northern Territory; NTHi, non-typeable Haemophilus
inﬂuenzae; OM, otitis media; OME, otitis media with effusion; PCV13, 13-valent pneu-
mococcal conjugate vaccine; PCV7, 7-valent pneumococcal conjugate vaccine; PHiD-
CV10, 10-valent pneumococcal Haemophilus inﬂuenzae protein D conjugate vaccine;
PPV23, 23-valent pneumococcal polysaccharide vaccine; Prevenar® and Prevenar 13®,
trademarks of Pﬁzer Inc; RD, risk difference; SD, standard deviation; Synﬂorix®, trade-
mark of the GlaxoSmithKline group of companies; TMP, tympanic membrane
perforation
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at least one form of otitis media remained high, there has been a
steady decline in the prevalence of TMP (either acute otitis media
with perforation (AOMwiP), dry perforation (DP), or chronic sup-
purative otitis media (CSOM)), from 24% in 2001 (pre-PCV) to 17%
in children vaccinated with 7-valent PCV (PCV7) to 14% in chil-
dren vaccinatedwith 10-valent pneumococcalHaemophilus inﬂuenzae
protein D-conjugate vaccine (PHiD-CV10) [1,2]. Streptococcus
pneumoniae (Spn, pneumococcus) and non-typeable H. inﬂuenzae
(NTHi) are major pathogens detected by culture [3,4] or PCR [5] in
ear discharge of children with TMP. Staphylococcus aureus (Sa) is also
a common (secondary) pathogen in ear discharge [6], whereas
Moraxella catarrhalis is rarely cultured or detected by PCR [5]. PCV7
has greatly reduced vaccine-serotype invasive pneumococcal disease
(IPD) and provides indirect protective effects via reduced vaccine
type carriage [7]. Replacement by non-vaccine serotypes [8] has
limited the extent and persistence of this beneﬁt [9]. The data from
a trial of 11-valent pneumococcal protein D-conjugate vaccine (11Pn-
PD) [10,11] including tympanocentesis for culture of middle ear ﬂuid
showed signiﬁcant protection against NTHi otitis media (OM) [10].
The re-formulated 10-valent vaccine (with serotype 3 removed) has
8 serotypes conjugated to protein-D. Immunogenicity and animal
model studies comparing 11Pn-PD and PHiD-CV10 indicated that
similar NTHi protection could be expected [11]. Although Austra-
lian regulatory authorities did not approve a license indication for
NTHi-OM [12], the NT infant vaccination schedule was changed in
2009 from a combination PCV7/PPV23 to a 3 + 1 PHiD-CV10 sched-
ule. This was followed in 2011 by a national shift to a 3 + 0 PCV13
schedule, plus a booster dose for Indigenous children (see Table 1).
Through ongoing surveillance, we observed 12% less suppurative
OM (AOMwoP, AOMwiP or CSOM) and 10% more OME in the PHiD-
CV10 group compared to PCV7-vaccinated children [2]. This shift
from suppurative OM to OME was associated with 27% less middle
ear NTHi infection, although there was no difference in NTHi car-
riage [6]. Our primary hypotheses for this subsequent comparison
of PHiD-CV10with PCV13 cohorts were that in children 6–36months
of age, the prevalence of suppurative OM andNTHi-associatedmiddle
ear infection would be lower, and the prevalence of bilateral normal
middle ears would be higher in PHiD-CV10 vaccinated children com-
pared to PCV13 vaccinated children. We also report ﬁndings from
general child health checks that are provided as a service by the re-
search nurses.
2. Methods
2.1. Study design, setting, community recruitment and ethical
approval
Since 2001 a total of thirty ﬁve remote communities in the NT
[8] and one in Western Australia have participated in at least one
community-based cross sectional survey of OM and NP carriage. This
report includes data from 25 Top End communities participating
between February 2010 and August 2013. The study was ap-
proved by the Human Research Ethics Committee of the Northern
Territory Department of Health and the Menzies School of Health
Research (EC00153), and the Western Australian Aboriginal Health
Information and Ethics Committee (WAAHIEC). Each community
council provided written approval of the study to the ethics
committee.
2.2. Participant recruitment and consent
Informed consent was sought from parents of all children less
than 6 years of age (regardless of ear health status or history) for
their child to have an ear examination, nasal swab, swab of ear dis-
charge if present, and general child health check. Parents or carers
were also asked for permission to access themother’s and the child’s
medical records and complete a lifestyle interview regarding in-
formation on likely risk or protective factors for otitis media.
2.3. Inclusion and exclusion criteria
Aboriginal children between 0 and 6 years of age, resident in par-
ticipating communities, were eligible for surveillance. For this report
we limit analysis as described below (Statistical analysis).
2.4. Clinical assessments
2.4.1. Ear examinations and general health assessments
All clinical assessments were made by ear health research nurses
with extensive training in the diagnosis and management of OM
in this population. Otoscopic ﬁndings were recorded on a standard-
ised form. Assessments were made using a tympanometer (Grason
Stadler GSI 38), a LumiView (Welch Allyn) with Siegel’s speculum
for pneumatic otoscopy, and a video-otoscope (Welch Allyn
macroview or MedRx video-otoscopes).
2.4.2. General health measures
Common conditions of childhood were recorded at the time of
ear assessment by direct observation; the child’s skin (head, arms,
legs and trunk) was examined for the presence of scabies, tinea, skin
sores or other skin condition; presence of nasal discharge (visible
at a distance of 1 meter), and any cough (spontaneous or cough on
request, either wet or dry). We categorised ‘not sure’ as absent. An-
tibiotics and other treatments or referrals were provided to
participants according to local guidelines.
2.4.3. Deﬁnitions of OM
Wecategorisedmiddle ear states as follows: (1) normal; (2) otitis
media with effusion (OME); (3) acute otitis media without perfo-
ration (AOMwoP); (4) AOM with perforation (AOMwiP); (5) dry
perforation (DP); and (6) chronic suppurative otitis media (CSOM).
The ﬁnal middle ear diagnosis reﬂected the child’s more severely
affected ear (highest category). We based our criteria for diagnosis
on recommendations for clinical practice in this population [13]:
(i) OME – intact and non-bulging tympanic membrane (TM) and
Type B tympanogram; (ii) AOMwoP – any bulging of the TM and
Type B tympanogram; (iii) AOMwiP – middle ear discharge ob-
served and TM perforation recently healed or present for less than
six weeks or covering less than 2% of the pars tensa of the TM; (iv)
dry perforation – TM perforation without any discharge observed;
(v) CSOM –middle ear discharge observed and perforation present
for longer than six weeks and covering at least 2% of the pars tensa
of the TM. We also include combination categories of any suppu-
rative OM (any AOM, AOMwiP or CSOM) and any TMP (any AOMwiP,
dry perforation or CSOM). Where duration of discharge was not
known, size of perforation was used to distinguish AOMwiP and
CSOM. Where otoscopy was not successful, we used the child’s
tympanometry result and deﬁned the child’s status as OME if either
ear had a Type B tympanogram.We asked themother if she thought
her child had ear pain that day or during the previous evening. These
a priori diagnostic criteria have been applied in all our surveillance
and clinical trials conducted in this population since 2001 [1].
Table 1
Pneumococcal vaccines in the childhood vaccination schedule for Northern Terri-
tory Indigenous children.
Date commenced Vaccine Age (mo)
1 July 2001 PCV7 and PPV23 2, 4, 6 18
1 October 2009a PHiD-CV10 2, 4, 6, 18
1 October 2011 PCV13 2, 4, 6, 18
a No other Australian jurisdiction recommended that PHiD-CV10 replace PCV7.
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2.4.4. Medical record review
The child’s medical records were reviewed to obtain dates of vac-
cinations, recent clinic presentations, antibiotics prescribed within
the previous 5 weeks, sex, gestational age, date of birth, birth weight,
and latest haemoglobin result.
2.5. Microbiology
Nasopharyngeal (NP) swabs were collected, transported and
stored as previously described [14] and in accordance with theWHO
recommendations for pneumococcal NP carriage studies [15]. Swabs
of ear discharge (ED) were collected after cleaning the external canal
and collecting discharge from as close as possible to the TMP [14].
NP and ED swabswere cultured on selective and non-selectivemedia
and semi-quantitative colony counts were recorded as previously
described [14]. For ED swabs with swarming species that pre-
cluded selection of single colonies of presumptive non-typeable
H. inﬂuenzae (NTHi), a millipore ﬁltration step was used [14]. At least
2 presumptive Spn colonies and 2 presumptive NTHi colonies were
selected from each specimen for conﬁrmation. Colonies of minor-
ity colony morphology were chosen if present. Single colonies of
Sa and Mcat were selected on the basis of colony morphology; Sa
was conﬁrmed if coagulase positive, Mcat was conﬁrmed if beta-
lactamase positive. Pneumococci were identiﬁed by colony
morphology, optochin sensitivity and positive reaction with typing
sera (Statens Serum Institut, Denmark); serotype was determined
by Quellung reaction. NTHi were identiﬁed by colony morpholo-
gy, dependence on X and V growth factors, and Phadebact
agglutination. PCR discrimination of Haemophilus haemolyticus was
not uniformly undertaken after conﬁrmation that less than 0.2% of
presumptive NTHi isolates from NP swabs in this population is mis-
identiﬁed [16]. Antimicrobial susceptibility was determined by the
calibrated dichotomous susceptibility (CDS) disc diffusion method
[17,18]. Minimum inhibitory concentrations (MICs) were deter-
mined for macrolide and beta-lactam antibiotic resistance in Spn
isolates and azithromycin resistance in NTHi isolates using Etest strips
(AB bioMérieux, Sweden). Beta-lactamase production by NTHi was
determined using nitrocephin (Oxoid, Australia). Resistance was
deﬁned using the European Committee on Antimicrobial Suscep-
tibility Testing (EUCAST) breakpoints (http://www.eucast.org).
Penicillin non-susceptibility of Spn was deﬁned as MIC > 0.06 mg/L
and azithromycin resistance as MIC > 0.5 mg/L. Azithromycin re-
sistance in NTHiwas deﬁned asMIC > 4mg/L; intermediate resistance
asMIC > 0.12mg/L and ≤ 4mg/L, and susceptibility asMIC ≤ 0.12mg/L.
2.6. Risk factor questionnaires
The parent or guardian (usually the mother) was asked a stan-
dardised set of questions about common risk factors for OM,
including the number of siblings, number of people and children
(less than 5 years of age) living in the child’s house, whether the
mother or child’s siblings had ever had TMP (“runny ears”), her
highest level of education, if she smoked, and whether the child was
exposed to campﬁre smoke within the previous week, the number
of days per week that the child attended child care, whether the
child washed with soap the previous day, had ever used a paciﬁer,
or was ever breastfed.
2.7. Statistical analysis
We compared childrenwho had received at least 2 doses of PHiD-
CV10 with children who had received at least 2 doses of PCV13 as
their primary course vaccines, with or without a subsequent single
dose of an alternative PCV. For this analysis we included children
0–36 months of age.
Conﬁdence intervals (CI, 95%) and risk differences (RD, 95% CI)
were calculated where appropriate. Stata version 12 was used for
all data analyses [19].
Univariate odds ratios and multivariate logistic regression ad-
justing for community were undertaken to examine risk factors for
any suppurative OM. Children with dry perforation were ex-
cluded. A global test was performed for categorical risk factors.
2.7.1. Missing data
If participants declined a clinical assessment or a swab, the data
were coded as missing. If parents or carers refused or were unsure
of their response to an interview question, we also coded this as
missing. Missing data were then excluded from the denominator
for summary statistics.
2.7.2. Funding
The study was funded by GlaxoSmithKline for the years 2010–
2012, and by Pﬁzer for 2013.
3. Results
3.1. Participant exclusions and PCV vaccination status
We enrolled 764 age-eligible children. We excluded 113 chil-
dren on the basis of their vaccination status; 36 children who had
not been vaccinated, 35 who had only a single dose of one or both
vaccines, 10 children who had received two doses of each vaccine,
and one child who had received two or more doses of more than
one PCV. Of the 651 children included, 511 were in the PHiD-
CV10 group and 140 in the PCV13 group. All had received two or
more doses of appropriate vaccine and not more than one dose of
any other PCV. Most children had received three or more PHiD-
CV10 (433/511, 85%) or PCV13 (103/140, 74%) doses; 81 (16%) PHiD-
CV10 children also had a booster dose compared to 14 (10%) PCV13
children (Table 2).
3.2. Region and communities
All 26 communities were in the tropical Top End region of Aus-
tralia. Visits by trained research nurses weremade each year between
early February andmid-December, themajority being between April
and December, during the dry and pre-cyclone seasons. The sam-
pling strategy resulted in differing proportions of children from
communities and regions over time. Large communities from 4
regions contributed 58% of the data in the PHiD-CV10 group and
Table 2
Number of doses of PCV7, PHiD-CV10 and PCV13 received by PHiD-CV10 children,
PCV13 children and excluded children.
Doses of PCV13 +PCV7a
0 1 2 3 4 TOTAL
Doses of
PHiD-CV
0 36b 14b 27 80 14 121
1 17b 4b 10 9 0 19
2 56 22 10b 78 23
3 235 118 1b 353 16
4 78 2 80 1
TOTAL 369 142 37 89 14 651
Bold values are included schedules.
PCV7, 7-valent pneumococcal conjugate vaccine; PHiD-CV10, 10-valent pneumo-
coccal Haemophilus inﬂuenzae protein D conjugate vaccine; PCV13, 13-valent
pneumococcal conjugate vaccine.
Included mixed schedules:
a 40 PHiD-CV10 children had also received one dose of PCV7 (ceased in October
2010).
Excluded schedules:
b 113 children were excluded; 82 shown, plus 31 (not shown) that received 2 doses
of PHiD-CV10 and 2 or 3 doses of PCV7.
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50% in the PCV13 group. One region contributed 24% of the data
in the PCV13 group compared to 8% in the PHiD-CV10 group.
3.3. Participant characteristics, general health and OM risk factor
prevalence
3.3.1. Age, gestational age, birth weight and gender
The mean ages were 19.0 and 13.3 months for PHiD-CV10 and
PCV13 groups, respectively. Mean gestational age and mean birth
weight were 37.7 and 38.1 weeks and 3.06 and 3.01 kg, respective-
ly. Overall, 51% were female (Table 3).
3.3.2. General health
Many children had health problems in addition to their ear
disease. There were no signiﬁcant differences in general health
between vaccine groups. Overall, 36% of children had a skin problem,
mainly impetigo (19%) or scabies (13%), 47% had visible runny nose,
and 38% of children were diagnosed with cough, predominantly wet
cough (30%). Abnormal haemoglobin (<11 g/dL) was recorded for
35% of children tested. Antibiotics, predominantly beta-lactams, had
been prescribed within 5 weeks of clinical assessment for 41% of
PHiD-CV10 children and 44% of PCV13 children (Table 3).
3.3.3. Risk factor questionnaire respondents
In the PHiD-CV10 group, 355 of 501 (71%) parents or carers who
were approached consented compared to 125 of 139 (90%) in the
PCV13 group (Supplementary Table S1).
3.3.4. Comparison of risk factor prevalence among PHiD-CV10 and
PCV13 respondent subgroups
Total household occupancy (8 persons per household) and the
mean number of children less than 5 years of age per household
(2 children) were not signiﬁcantly different between the PCV
groups. Other measures of household crowding (proportion with
>2 additional children < 5 years of age, 22% overall) and child care
attendance (17% overall) were not signiﬁcantly different between
PHiD-CV10 and PCV13 groups (Supplementary Table S1). For both
vaccine groups, almost all children (~90%) washed with soap the
previous day, around 30% of children had a sibling with a history
of CSOM (‘runny ears’) and most mothers (~60%) smoked ciga-
rettes. Signiﬁcantly more children in the PCV13 group (53% versus
34%, p = 0.0004) had been exposed to campﬁre smoke. Mean
maternal age was ~26 years, 60% of the mothers completed school
years 11 or 12, and one in four had a short course certiﬁcate as
their highest level of formal education. Very few babies were
never breastfed (~6%), and paciﬁer use (~12%) was relatively
uncommon (Supplementary Table S1).
3.4. Primary outcome: otitis media prevalence, by vaccine group and
age
At least ninety six per cent of children in each group had at least
one ear successfully assessed (Table 4). One child had a diagnosis
based on tympanometry alone. In both groups, less than 10% had
bilateral normal middle ears. A diagnosis of OME was made for 52%
of PHiD-CV10 children and 50% of PCV13 children; AOMwoP was
diagnosed for 24% and 31%, AOMwiP for 5% and 3%, dry perfora-
tion for 2% and 3%, and CSOM for 7% and 6%, respectively. Of the
476 PHiD-CV10 children and 130 PCV13 children with bilateral oto-
scopic assessments, 249 (52%) and 65 (50%) had worse ear diagnosis
of OME. Of these, almost all had bilateral OME (86% and 94%,
respectively).
For combination diagnostic categories, any suppurative OMwas
diagnosed in 36% of the PHiD-CV10 group and 40% of the PCV13
group (RD 3% [95% CI −6 to 13] p = 0.47). The PCV groups had similar
rates of TMP (14% versus 12%. RD −3% [95% CI −9 to 2] p = 0.39).
Overall, very few of the 524 interviewedmothers (7%) reported that
their child had had ear pain on the day or during the night prior
to the ear assessment (Table 4). The proportion of assessments as-
sociated with ear pain reported by the mother was higher for
children with AOMwiP (6/23, 26%) than for children with OME (11/
260, 4%) or bilateral normal ears (2/52, 4%).
Table 3
Participant characteristics, general health and antibiotics prescribed, by vaccination group.
PHiD-CV10 PCV13 Absolute difference
[95% CI]
p
N Mean (SD) or % N Mean (SD) or %
Age (mo) 511 19.0 140 13.3 5.7 [ 4 to 7] <0.0001
0 to <3 0 0
3 to <6 10 2% 11 8%
6 to <9 61 12% 29 21%
9 to <12 47 9% 26 19%
12 to <18 126 25% 46 33%
18 to <24 109 21% 18 13%
24 to <36 158 31% 10 7%
Gestational age (weeks) 378 37.7 (2.8) 426 38.1(2.3) 0.4 [ 0 to 0.7] 0.04
Birth weight (kg) 489 3.06 (0.60) 133 3.01
(0.66)
0.05 [ −0.07 to 0.17] 0.2
Sex (female) 69 49% 251 49% 0.1% [−10 to 9] 0.97
General health
Skin assessed 495/511 97% 139/140 99%
Normal 328 66% 80 58% −9% [−18 to 0.5] 0.06
Scabies 60 12% 20 15% 2% [−4 to 9] 0.45
Impetigo 89 18% 31 22% 4% [−3 to 612] 0.24
Tinea 16 3% 4 3% 0.3% [−4 to 3] 0.84
Other 37 8% 12 9% 1% [−4 to 7] 0.60
Other
Runny nose 232/505 46% 74/140 53% 7% [−2 to 16] 0.15
Any cough 190/506 38% 56/140 40% 2% [−7 to 12] 0.60
Any antibiotics prescribed in previous 5 weeks 208/511 41% 62/140 44% 4% [−6 to 13] 0.46
Beta-lactam 172/511 34% 49/140 35% 1.3% [−8 to 10] 0.77
Macrolide 19/511 4% 8/140 6% 2% [−2 to 6] 0.29
Topical 21/511 4% 4/140 3% 1% [−5 to 2] 0.49
Haemoglobin (<11 g/dL) 155/461 34% 47/120 39% 6% [−4 to 15] 0.26
Bold values are p-values.
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Adjustment for age made no substantial difference to these ﬁnd-
ings (e.g. for any suppurative OM, odds ratio unadjusted 1.2 [95%
CI 0.8–1.7], OR age adjusted 0.9 [95% CI 0.6–1.4]).
Comparisons of OM prevalence between recipients of non-
mixed PCV schedules (318 PHiD-CV10 recipients and 120 PCV13
recipients who had at least one ear assessed) showed almost iden-
tical ﬁndings. Prevalence of TMP was 9% in the PCV13 group,
compared to 15% in the PHiD-CV10 group (Table 4), but this did not
reach statistical signiﬁcance (p = 0.09), including after adjustment
for age (p = 0.12).
Among the 80 PHiD-CV10 recipients (mean age 26 months [95%
CI 9–35]) who also had a PHiD-CV10 booster dose, 14% had bilat-
eral normal ears, 54% had OME, 14% had AOMwoP and 13% had
tympanic membrane perforation (6% were not seen). Among the 14
PCV13 recipients (mean age 20 months [95% CI 12–23]) who also
had a PCV13 booster dose, these ﬁgures were 21%, 50%, 14% and
14%, respectively (data not shown).
3.4.1. Age and any suppurative OM, by vaccine group
No signiﬁcant difference between PHiD-CV10 and PCV13 groups
in the prevalence of suppurative OM was seen for any age group;
50% versus 47%, respectively in children less than 12 months of age,
38% versus 37% in children 1 to <2 years of age, and 24% versus 20%
in children 2 to <3 years of age (data not shown).
3.5. Univariable and multivariable analyses of risk factors for any
suppurative OM
In a univariate analysis adjusting for community, only older age
was protective of suppurative OM (odds ratio 0.31 [95% CI 0.19–
0.51] for 2–3 year olds compared to infants less than 12 months
of age, p < 0.0001). None of the other measured predictors was sig-
niﬁcant, including PCV group (Supplementary Table S2). Multivariate
analyses did not change these ﬁndings.
3.6. Nasopharyngeal carriage
NP swabs were collected from 499 PHiD-CV10 children and 136
PCV13 children. No differences in the prevalence of NP carriage were
found for NTHi, Spn, M. catarrhalis or Staphylococcus aureus (Sa)
(Table 5). Fewer PCV13 children were co-colonised by both NTHi
and Spn (62% and 51%, RD −10% [95% CI −20 to −1] p = 0.03]; 89%
of each group had one or other of NTHi or Spn.
Serotype 16F was predominant in PHiD-CV10 children (14% iso-
lates 11% NP swabs) and in PCV13 children (23% isolates 16% NP
swabs) (Fig. 1, Table 5). Serotype 19A was the secondmost common
serotype in the PHiD-CV10 group and was still present in PCV13
children, whereas 19F was only detected in the top ten serotypes
of PCV13 children. PCV13-serotypes colonised the NP of 21% of PHiD-
CV10 children compared to 15% of PCV13-vaccinated children (RD
−6% [95% CI −14 to 2] p = 0.18) (Fig. 2).
In the subgroup of children receiving non-mixed 3-dose PCV
schedules, the PCV13 group had signiﬁcantly less NTHi carriage
(73% versus 58% RD −15% [95% CI −25 to −5] p = 0.003; OR = 0.5
[95% CI 0.33–0.79]). Adjustment for age did not change this
ﬁnding (OR age adjusted = 0.5 [95% CI 0.33–0.84]). Small differ-
ences in NP carriage of other otopathogens did not reach statistical
signiﬁcance.
3.7. NP carriage associations
To explore potential interactions among NP pathogens, we com-
pared co-colonisation associations independent of the PCV group.
Children colonised by Spn, compared to children not Spn-colonised,
were more likely to also have NTHi (75% versus 48% OR age ad-
justed = 3.3 [95% CI 2.2–5.0]) and more likely to be colonised with
Mcat (49% versus 25% OR age adjusted = 2.9 [95% CI 1.8–4.4]). Con-
versely, children colonised by Spn were less likely to also have Sa
than those not Spn-colonised (18% versus 26% OR age adjusted = 0.62
Table 4
Prevalence of otitis media including combination categories of any suppurative OM, any TMP, and any pain, by vaccination groups.
PHiD-CV10
511
PCV13
140
Absolute difference
[95% CI]
P value
n % n %
No. children without assessment 17 3% 1 1%
No. children with diagnosis based on tympanometry alone 0 0% 1 1%
No. children with unilateral otoscopy 18 4% 8 6%
No. children with bilateral otoscopy 476 93% 130 93%
No. children with at least one ear successfully assessed 494 96% 139 97%
Clinical diagnosis PHiD-CV10
494
PCV13
139
Normal 49 10% 10 7% −3% [−8 to 2] 0.33
OME 257 52% 70 50% −2% [−11 to 8] 0.73
AOMwoP 117 24% 43 31% 7% [−1 to 16] 0.08
AOMwiP 25 5% 4 3% −2% [−6 to 1] 0.28
Dry Perforation 9 2% 4 3% 1% [−2 to 4] 0.44
CSOM 37 7% 8 6% −2% [−6 to 3] 0.48
Bilateral OMEa 213 45% 61 47% 2% [−12 to 7] 0.66
Unilateral OMEa 36 8% 4 3% −4% [0.6 to 8] 0.07
Combination OM categories
Any suppurative OM (AOMwoP, AOMwiP, CSOM) 179 36% 55 40% 3% [−6 to 13] 0.47
Any TMP (AOMwiP, DP, CSOM) 71 14% 16 12% −3% [−9 to 3] 0.39
Any ear pain (today or last night) 27/396 7% 11/128 9% 2% [−4 to 7] 0.50
Non-mixed PCV schedules PHiD-CV10-only
329
PCV13-only
121
No. children with at least one ear successfully assessed 318 97% 120 99%
Normal 31 10% 9 8% −2% [−8 to 3] 0.47
OME 158 50% 60 50% 0.3% [−10 to 11] 0.95
Any suppurative OM (AOMwoP, AOMwiP, CSOM) 124 40% 48 41% 1% [−9 to 12] 0.79
Any TMP (AOMwiP, DP, CSOM) 49 15% 11 9% −6% [−13 to 0.2] 0.09
a Laterality of OME could only be determined where bilateral assessments were successful.
Adjustment for age made no substantial difference to these ﬁndings.
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[95% CI 0.39–0.98] p = 0.039]). We also observed a negative asso-
ciation between NTHi and Sa (OR age adjusted = 0.42 [95% CI 0.28–
0.63]) and to some degree between Mcat and Sa (OR age
adjusted = 0.63 [95% CI 0.42–0.96]). Serotype 10A (n = 25) was pos-
itively associated with Sa (OR age adjusted = 2.56 [95% CI 1.08–
6.06], p = 0.032), whereas serotype 19A (n = 36) was negatively
associated (OR age adjusted = 0.38 [95% CI 0.11–1.27], p = 0.12) and
carriage of serotypes 15A (n = 32), 11A (n = 37) and 16F (n = 79) were
not different in Sa carriers and Sa non-carriers.
3.8. Microbiology of middle ear discharge
Seventy one children in the PHiD-CV10 group and 16 children
in the PCV13 group had a worse ear diagnosis of any TMP (Table 4).
We obtained at least one specimen of ear discharge (ED) from 51
(72%) and 11 (69%) children, respectively, providing a total of 63 and
14 ED swabs, respectively.
Analysis of ED swabs showed signiﬁcantly higher recovery of
NTHi from PCV13 specimens compared to PHiD-CV10 (9/14, 64%
Table 5
Prevalence of NP carriage of OM pathogens in NP-swabbed children, by vaccination group.
PHiD-CV10
511
PCV13
140
Absolute difference
[95% CI]
P value
n/N % n/N %
NP swabs 499 (98%) 136 (97%)
NP carriage
NTHi 356 71% 86 63% −8% [−17 to 0.9] 0.07
Spn 402 81% 105 77% −3% [−11 to 5] 0.39
Mcat 218 44% 61 45% 1% [−8 to 10] 0.84
Sa 101 20% 22 16% −4% [−11 to 3] 0.29
Combination NP carriage categories
Spn and NTHi 311 62% 70 51% −10% [−20 to −1] 0.03
Spn or NTHi 477 89% 121 89% 0% [−6 to 6] 0.98
PCV7 types 36/414 9% 12/102 12% 3% [−4 to 10] 0.34
PCV13 types 85/414 21% 15/102 15% −6% [−14 to 2] 0.18
Top 7 serotypes(%)a 16Fc(14%) 19Ac,d(8%) 11Ac,d(7%) 10Ac(6%)
6Cb(5%) 15Ac,d(5%) 23Fb,c,d(5%)
16Fc(23%) 15Ac,d(10%) 23Fb,c,d(6%) 11Ac,d(6%)
35Bc(6%) 19Fc,d(5%) 15Bc(5%)
Non-mixed PCV schedules
NP carriage 324 118
NTHi 237 73% 69 58% −15% [−25 to −5] 0.003
Spn 266 82% 90 76% −6% [−15 to 3] 0.15
Mcat 132 41% 50 42% 2% [−8 to 13] 0.67
Sa 71 22% 20 17% −5% [−13 to 3] 0.25
Bold values are p-values.
a Strains within serotypes that are:
b Azithromycin non-susceptible (MIC > 0.5 mg/L).
c Penicillin non-susceptible (MIC > 0.06 mg/L).
d Non-susceptible to both.
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versus 21/59, 36%). There was also a higher recovery of Spn (6/14,
43% versus 10/69, 17%) from PCV13 specimens, but signiﬁcantly
lower prevalence of Sa middle ear infections (1/14, 7% versus 24/
60, 40%). No difference in Mcat (1/14, 7% versus 5/59, 8%) was
detected (Table 6).
In a comparison of data by child (data combined if bilateral), dif-
ferences were smaller and no longer statistically signiﬁcant, with
the exception of Sa (1/11, 9% versus 22/49, 45%) (Table 6).
Pneumococcal serotypes were 11A(3 isolates), 15A(2) and one
isolate each of serotypes 16F, 19F, 21, 22A and 35F in the PHiD-
CV10 group, and 33F(2), 9N(2), 1(1), and 35B(1) in the PCV13 group.
4. Discussion
Following a prior comparison of PHiD-CV10with PCV7-vaccinated
children, in which a signiﬁcant reduction in suppurative OM was
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Table 6
Prevalence of OM pathogens in 75 ear discharge (ED) swabs from 62 children with AOMwiP or CSOM, by vaccination groups.
PHiD-CV10 PCV13 Absolute difference
[95% CI]
P value
N, Mean (SD) % N, Mean (SD) %
ED swabs 63 14
Children with ED 51 11
Mean age (mo) 18.6 (5.8) 15.3 (8.5)
Bilateral ED swabs 26 6
Bilateral CSOM 16 6
Bilateral AOMwiP 6 0
AOMwiP and CSOM 4 0
All ED swabs
NTHi 21/59 36% 9/14 64% 29% [0.8 to 57] 0.05
Spn 10/60 17% 6/14 43% 26% [−1 to 54] 0.03
NTHi and Spn 7/59 12% 6/14 43% 31% [4 to 58] 0.006
Mcat 5/59 8% 1/14 7% −1% [−17 to 14] 0.87
Sa 24/60 40% 1/14 7% −33% [−51 to −15] 0.02
Spn serotypes (n)a 11Ad(3) 15Ad(2) 16Fc 19Fd 21b 22A 35F 33F(2) 1(1) 9N(2) 35Bc(1)
Children with ED (data combined if bilateral)
NTHi 17/48 35% 6/11 55% 19% [−13 to 52] 0.24
Spn 10/49 20% 4/11 36% 16% [−15 to 47] 0.26
NTHi and Spn 7/49 14% 4/11 36% 22% [−8 to 52] 0.09
Mcat 4/48 8% 1/11 9% 1% [−18 to 19] 0.94
Sa 22/49 45% 1/11 9% −36% [−58 to −14] 0.02
Bold values are p-values.
a Strains within this serotype are:
b Azithromycin non-susceptible (MIC > 0.5 mg/L).
c Penicillin non-susceptible (MIC > 0.06 mg/L).
d Non-susceptible to both.
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reported in association with PHiD-CV10 vaccination [2], and for
whom less NTHi was cultured from middle ear discharge [6], we
anticipated that PCV13-vaccinated children, who would not have
vaccine-induced anti-HiD antibody protection fromNTHi, would have
an increased prevalence of suppurative OM, increased NTHi middle
ear infection, and possibly increased NP carriage of NTHi. What we
did ﬁnd was that compared to the PHiD-CV10 group, PCV13-
vaccinated children had a similar prevalence of suppurative OM
(around 40%), a higher prevalence of middle ear co-infection with
NTHi and Spn (signiﬁcant for comparison by ear) and less NTHi NP
carriage (signiﬁcant when 3-dose schedules compared). Whilst not
statistically signiﬁcant, the PCV13 group had a lower TMP preva-
lence (particularly for the 3-dose comparison) of 9% compared to
15% in the PHiD-CV10 group. Compared with our earliest (2001)
pre-PCV7 OM surveillance, when the prevalence of TMP was 24%
among children of this age [1], the ﬁndings are encouraging. These
somewhat positive clinical ﬁndings are not entirely consistent with
themicrobiology of the middle ear discharge, since the PCV13 group
had signiﬁcantly more Spn and NTHi mixed middle ear infection.
It is possible that the lower prevalence of TMP in the PCV13 group
was related to the signiﬁcantly lower prevalence of S. aureusmiddle
ear infection.
As mentioned we continue to ﬁnd that almost every child has
some form of OM and that less than 10% of children have bilater-
ally normalmiddle ear status.UnilateralOME,where the contralateral
ear is normal, would not meet criteria for hearing assessment and
could be considered normal in audiological terms. However, of the
50% of children with a diagnosis of OME in their worse ear, almost
all (90%) had bilateral OME. Of the 21 infants under the age of 6
months, and a further 90 infants between the ages of 6 and9months,
half had a diagnosis of suppurative OM. This early onset remains a
huge challenge and requires new strategies for prevention. It is in-
triguing that OM is so rarely associated with pain as reported by
the child’s mother. Asymptomatic AOM in this population has been
documented overmany yearswith translation to national OMguide-
lines [13], health care provider training and community awareness
campaigns [20] that promote ear assessments for all high risk chil-
dren regardless of the primary reason for presentation. Failure to
recognise and treat asymptomatic AOMmay explain in part the pro-
gression to tympanic membrane perforation and CSOM.
In addition to these ongoing ear health problems, one in four or
ﬁve children had impetigo, one in six had scabies, half had runny
nose and two in ﬁve had a cough. Antibiotics had been recently pre-
scribed for almost half the children. These children were generally
not considered unwell by their carer. Children were in their homes
and were not presenting for health services [13].
As previously discussed [2], limitations of our study are that sur-
veillance is dependent on annual community participation approval
processes, so whilst we have adjusted some group comparisons in
consideration of this diversity, it would be possible that over- or
under-representation of higher- or lower-risk communities could
inﬂuence our ﬁndings. Also, our non-random selection of children
for assessment could contribute to bias. Our a priori analysis plan
was to compare children who received predominantly one PCV for-
mulation or another in their primary 3-dose course. Comparisons
of OM prevalence between recipients of non-mixed 3-dose PCV
schedules showed very similar ﬁndings.
Failure to detect signiﬁcant vaccine group differences in clinical
or NP carriage was not inﬂuenced by group differences in classical
risk or protective factors such as crowding, smoke exposure or
breastfeeding. Younger children had the highest risk of suppurative
OM, but adjustment for age made no substantial differences to odds
ratios. As with our previous comparison of PCV7 and PHiD-CV10
vaccine groups, this comparison of cross sectional data from PHiD-
CV10 and PCV13 groups is made complex by the lack of concurrent
data. Factors notmeasuredmay also have changedduring this period.
Several studies have reported invasive pneumococcal disease, OM
andNP carriage outcomes of PCVRCTs [21–23] and pre- versus post-
changes in vaccination schedules [24–26]. In a RCT conducted in
the Netherlands [21], PHiD-CV10 had no impact on nasopharyn-
geal (NP) carriage prevalence or density of NTHi, whereas the Kiliﬁ
NP carriage cross sectional comparisons showed a signiﬁcant re-
duction in NTHi carriage after PHiD-CV10 was introduced to the
national immunisations program [24]. Paradoxically, we found that
NP carriage of NTHi was signiﬁcantly lower in the 3-dose PCV13
group,whereasmiddle ear infection and co-infection (NTHi and Spn)
rates were substantially higher in the PCV13 group than the PHiD-
CV10 group, as anticipated. In Israel, where PCV13 replaced PCV7,
rates of PCV13-serotype OM (conﬁrmed by tympanocentesis and
middle ear ﬂuidmicrobiology) declinedwith a small increase in non-
PCV13-serotype OM [25]. All-cause OM also declined substantially
in PCV13 compared to PCV7 children, which the authors presumed
to be due to reductions in co-infection with non-pneumococcal
otopathogens (non-pneumococcal infectionswerenot reported) [25].
Our ﬁndings from a small number of samples would also suggest
that reductions in S. aureus middle ear infection could be an un-
anticipatedoutcomeof PCV13vaccination, despite a lackof substantial
differences in NP carriage. Our failure to detect a change in S. aureus
NP carriage contrasts with data suggesting replacement NP car-
riage by S. aureus following PCV introduction and reducedVT carriage
(summarised in Ref. 27). Our analysis of all NP carriage data, inde-
pendent of PCV formulation, indicates positive associations among
the otopathogens Spn, NTHi and Mcat, contrasting with negative
associations between each of these otopathogens and S. aureus. Po-
tential for pneumococcal serotype-speciﬁc positive and negative
associations needs to be conﬁrmed.
Increased NTHi-speciﬁc immune responses to PHiD-CV10 in the
lungs of Indigenous children with chronic suppurative lung disease
(elevated IFNγ, IL13 and IL 5) [28] offer some insight as to the pos-
sible mechanisms of protection in the middle ear. Randomised
controlled vaccine trials with OM outcomes and concomitant studies
of both NP and middle ear microbiology are needed to clarify these
ﬁndings and substantiate the potential mechanisms involved in the
host response to HiD carrier protein of PHiD-CV10, and other pu-
tative NTHi and pneumococcal vaccine candidates as well as indirect
effects of vaccines on polymicrobial OM [29].
5. Conclusion
Our report of the general health and comparison of ear health
of children receiving PHiD-CV10 or PCV13 according to the NT child-
hood vaccination schedules shows no substantial change in the
prevalence of OM or TMP, and some differential effects on middle
earmicrobiology.Multivariate logistic regression did not change these
ﬁndings. Clinical trials of vaccines that offer broader coverage of OM
pathogens from an earlier age are needed in this high risk population.
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